Edition:
United States

Ignyta Inc (RXDX.OQ)

RXDX.OQ on NASDAQ Stock Exchange Capital Market

6.10USD
9 Dec 2016
Change (% chg)

$-0.30 (-4.69%)
Prev Close
$6.40
Open
$6.25
Day's High
$6.70
Day's Low
$6.05
Volume
53,159
Avg. Vol
42,122
52-wk High
$14.94
52-wk Low
$4.15

RXDX.OQ

Chart for RXDX.OQ

About

Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in... (more)

Overall

Beta: --
Market Cap(Mil.): $254.08
Shares Outstanding(Mil.): 41.65
Dividend: --
Yield (%): --

Financials

  RXDX.OQ Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -3.36 -- --
ROI: -69.33 -0.36 15.24
ROE: -92.26 -0.94 16.58

BRIEF-Ignyta announces EAP Designation and CE Marking for its Trailblaze Pharos clinical trial assay

* Ignyta announces EAP Designation and CE Marking for its Trailblaze Pharos(TM) clinical trial assay Source text for Eikon: Further company coverage:

Nov 15 2016

BRIEF-Ignyta Q3 loss per share $0.56

* Says did not record any revenue for three months ended Sept 30, 2016

Nov 07 2016

BRIEF-Ignyta announces approval of an Investigational Device Exemption

* Announces approval of an Investigational Device Exemption (IDE) for companion diagnostic assay to STARTRK-2 Trial Source text for Eikon: Further company coverage:

Aug 31 2016

BRIEF-Ignyta Q2 loss per share $0.70

* Ignyta announces second quarter 2016 company highlights and financial results

Aug 09 2016

BRIEF-Ignyta secures $42 million term loan facility

* Ignyta inc says received initial funding of $32 million, substantially all of which was used to repay company's prior loan with silicon valley bank

Jun 30 2016

Earnings vs. Estimates